Endogenous opioid systems alterations in pain and opioid use disorder

被引:23
|
作者
Higginbotham, Jessica A. [1 ,2 ,3 ]
Markovic, Tamara [4 ,5 ]
Massaly, Nicolas [1 ,2 ,3 ,8 ]
Moron, Jose A. [1 ,2 ,3 ,6 ,7 ]
机构
[1] Washington Univ, Dept Anesthesiol, St Louis, MO 63110 USA
[2] Washington Univ, Pain Ctr, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, St Louis, MO 63110 USA
[4] Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, New York, NY 10029 USA
[5] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA
[6] Washington Univ, Dept Neurosci, St Louis, MO USA
[7] Washington Univ, Dept Psychiat, St Louis, MO USA
[8] Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
opioids; pain; addicition; opioid use and abuse; opioid use disorder (OUD); reward; endogenous opioids; opioid receptors; VENTRAL TEGMENTAL AREA; CONDITIONED PLACE PREFERENCE; MESSENGER-RNA EXPRESSION; BETA-ENDORPHIN IMMUNOREACTIVITY; METHADONE-MAINTENANCE TREATMENT; TONIC DESCENDING FACILITATION; NOCICEPTIN/ORPHANIN FQ N/OFQ; NUCLEUS-ACCUMBENS; MORPHINE-TOLERANCE; SPINAL-CORD;
D O I
10.3389/fnsys.2022.1014768
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Decades of research advances have established a central role for endogenous opioid systems in regulating reward processing, mood, motivation, learning and memory, gastrointestinal function, and pain relief. Endogenous opioid systems are present ubiquitously throughout the central and peripheral nervous system. They are composed of four families, namely the mu (MOPR), kappa (KOPR), delta (DOPR), and nociceptin/orphanin FQ (NOPR) opioid receptors systems. These receptors signal through the action of their endogenous opioid peptides beta-endorphins, dynorphins, enkephalins, and nociceptins, respectfully, to maintain homeostasis under normal physiological states. Due to their prominent role in pain regulation, exogenous opioids-primarily targeting the MOPR, have been historically used in medicine as analgesics, but their ability to produce euphoric effects also present high risks for abuse. The ability of pain and opioid use to perturb endogenous opioid system function, particularly within the central nervous system, may increase the likelihood of developing opioid use disorder (OUD). Today, the opioid crisis represents a major social, economic, and public health concern. In this review, we summarize the current state of the literature on the function, expression, pharmacology, and regulation of endogenous opioid systems in pain. Additionally, we discuss the adaptations in the endogenous opioid systems upon use of exogenous opioids which contribute to the development of OUD. Finally, we describe the intricate relationship between pain, endogenous opioid systems, and the proclivity for opioid misuse, as well as potential advances in generating safer and more efficient pain therapies.
引用
收藏
页数:24
相关论文
共 50 条
  • [31] Opioid use disorder
    John Strang
    Nora D. Volkow
    Louisa Degenhardt
    Matthew Hickman
    Kimberly Johnson
    George F. Koob
    Brandon D. L. Marshall
    Mark Tyndall
    Sharon L. Walsh
    [J]. Nature Reviews Disease Primers, 6
  • [32] Autistic disorder and the endogenous opioid system
    Sher, L
    [J]. MEDICAL HYPOTHESES, 1997, 48 (05) : 413 - 414
  • [33] ENDOGENOUS OPIOID SYSTEMS IN BRAIN
    PASTERNAK, GW
    [J]. AMERICAN JOURNAL OF MEDICINE, 1980, 68 (02): : 157 - 159
  • [34] ENDOGENOUS OPIOID PEPTIDES AND THE CONTROL OF PAIN
    KOSTERLITZ, HW
    [J]. PSYCHOLOGICAL MEDICINE, 1979, 9 (01) : 1 - 4
  • [35] Associations Between Endogenous Opioid System Functioning and Polygenic Risk for Major Depression and Opioid Use Disorder
    Love, Tiffany
    Shabalin, Andrey
    Kember, Rachel
    Docherty, Anna
    Zhou, Hang
    Gelernter, Joel
    Baker, Anne
    Hartwell, Emily
    Dubroff, Jacob
    Zubieta, Jon-Kar
    Kranzler, Henry
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 511 - 511
  • [36] Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia
    Chen, Yun Han
    Xenitidis, Anastasios
    Hoffmann, Paul
    Matthews, Leslie
    Padmanabhan, Swathi G.
    Aravindan, Lakshmi
    Ressler, Ruth
    Sivam, Inesh
    Sivam, Sahana
    Gillispie, Chase F.
    Sadhasivam, Senthilkumar
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (5-6) : 455 - 465
  • [37] Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer
    Nicole Bates
    Jennifer K. Bello
    Nosayaba Osazuwa-Peters
    Mark D. Sullivan
    Jeffrey F. Scherrer
    [J]. Current Treatment Options in Oncology, 2022, 23 : 348 - 358
  • [38] What is Buprenorphine? How and why is it use for pain and for opioid use disorder?
    Reznikoff, Charles
    [J]. PAIN MANAGEMENT NURSING, 2024, 25 (02) : E157 - E157
  • [39] Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer
    Bates, Nicole
    Bello, Jennifer K.
    Osazuwa-Peters, Nosayaba
    Sullivan, Mark D.
    Scherrer, Jeffrey F.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (03) : 348 - 358
  • [40] Chronic pain in patients with opioid use disorder receiving methadone
    Samaan, Z.
    Dennis, B.
    Bawor, M.
    Bhatt, M.
    Zielinski, L.
    Sanger, N.
    Thabane, L.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 165 - 165